38 related articles for article (PubMed ID: 21931023)
1. The financial burden of accessing care for people with scleroderma in Canada: a patient-oriented, cross-sectional survey.
Trenaman L; Kaal KJ; Laba TL; Safari A; Aguiar M; Burch T; Beckett J; Munro S; Hudson M; Harrison M
CMAJ Open; 2023; 11(4):E630-E636. PubMed ID: 37437955
[TBL] [Abstract][Full Text] [Related]
2. Determining Burden of Commuting for Treatment Using Online Mapping Services - A Study of Breast Cancer Patients.
Cheng AC; Levy MA
AMIA Annu Symp Proc; 2017; 2017():555-564. PubMed ID: 29854120
[TBL] [Abstract][Full Text] [Related]
3. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
4. "It's at a time in your life when you are most vulnerable": a qualitative exploration of the financial impact of a cancer diagnosis and implications for financial protection in health.
Timmons A; Gooberman-Hill R; Sharp L
PLoS One; 2013; 8(11):e77549. PubMed ID: 24244279
[TBL] [Abstract][Full Text] [Related]
5. Patient and Family Financial Burden in Cancer: A Focus on Differences across Four Provinces, and Reduced Spending Including Decisions to Forego Care in Canada.
Longo CJ; Maity T; Fitch MI; Young JT
Curr Oncol; 2024 May; 31(5):2713-2726. PubMed ID: 38785487
[TBL] [Abstract][Full Text] [Related]
6. Proximity to Radiotherapy Center, Population, Average Income, and Health Insurance Status as Predictors of Cancer Mortality at the County Level in the United States.
Beckett M; Goethals L; Kraus RD; Denysenko K; Barone Mussalem Gentiles MF; Pynda Y; Abdel-Wahab M
JCO Glob Oncol; 2023 Sep; 9():e2300130. PubMed ID: 37769217
[TBL] [Abstract][Full Text] [Related]
7. The many "costs" of transportation: Examining what cancer caregivers experience as transportation obstacles.
Thomson MD; Van Houtven CH; Xu R; Siminoff LA
Cancer Med; 2023 Aug; 12(16):17356-17364. PubMed ID: 37485648
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
Li Y; Liang X; Yang T; Guo S; Chen X
Front Oncol; 2022; 12():878054. PubMed ID: 36226060
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.
Salans M; Courtney PT; Yip A; Murphy JD
Cancer Med; 2021 Oct; 10(19):6618-6626. PubMed ID: 34402192
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
11. Patient and family financial burden associated with cancer treatment in Canada: a national study.
Longo CJ; Fitch MI; Loree JM; Carlson LE; Turner D; Cheung WY; Gopaul D; Ellis J; Ringash J; Mathews M; Wright J; Stevens C; D'Souza D; Urquhart R; Maity T; Balderrama F; Haddad E
Support Care Cancer; 2021 Jun; 29(6):3377-3386. PubMed ID: 33403399
[TBL] [Abstract][Full Text] [Related]
12. A theoretical model of financial burden after cancer diagnosis.
Jones SM; Henrikson NB; Panattoni L; Syrjala KL; Shankaran V
Future Oncol; 2020 Dec; 16(36):3095-3105. PubMed ID: 32976048
[TBL] [Abstract][Full Text] [Related]
13. Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review.
Longo CJ; Fitch MI; Banfield L; Hanly P; Yabroff KR; Sharp L
Support Care Cancer; 2020 Oct; 28(10):4645-4665. PubMed ID: 32653957
[TBL] [Abstract][Full Text] [Related]
14. Pre-diagnosis employment status and financial circumstances predict cancer-related financial stress and strain among breast and prostate cancer survivors.
Sharp L; Timmons A
Support Care Cancer; 2016 Feb; 24(2):699-709. PubMed ID: 26143038
[TBL] [Abstract][Full Text] [Related]
15. The global impact of non-communicable diseases on households and impoverishment: a systematic review.
Jaspers L; Colpani V; Chaker L; van der Lee SJ; Muka T; Imo D; Mendis S; Chowdhury R; Bramer WM; Falla A; Pazoki R; Franco OH
Eur J Epidemiol; 2015 Mar; 30(3):163-88. PubMed ID: 25527371
[TBL] [Abstract][Full Text] [Related]
16. Responses by breast and prostate cancer patients to out-of-pocket costs in Newfoundland and Labrador.
Housser E; Mathews M; Lemessurier J; Young S; Hawboldt J; West R
Curr Oncol; 2013 Jun; 20(3):158-65. PubMed ID: 23737684
[TBL] [Abstract][Full Text] [Related]
17. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.
Zafar SY; Peppercorn JM; Schrag D; Taylor DH; Goetzinger AM; Zhong X; Abernethy AP
Oncologist; 2013; 18(4):381-90. PubMed ID: 23442307
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
Rakovitch E; Nofech-Mozes S; Hanna W; Narod S; Thiruchelvam D; Saskin R; Spayne J; Taylor C; Paszat L
Br J Cancer; 2012 Mar; 106(6):1160-5. PubMed ID: 22361634
[TBL] [Abstract][Full Text] [Related]
19. Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer.
Lauzier S; Levesque P; Drolet M; Coyle D; Brisson J; Mâsse B; Robidoux A; Robert J; Maunsell E
J Clin Oncol; 2011 Oct; 29(30):4007-13. PubMed ID: 21931023
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
